Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic ...

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, ...

The research delves into how mutations in FGFR2 and FGFR3 affect mandibular ... Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients with FGFR2/3 mutations. With the growing emphasis on ...

Hutchmed (HCM) announced that it has completed enrollment of its a Phase II trial of fanregratinib for intrahepatic cholangiocarcinoma patients ...